AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38687741 — intervention group
Group type: COMPARATOR
Intervention: Control (Standard care only)
Number of subjects: 124
Study 38687981 — intervention group
Group type: EXPERIMENTAL
Intervention: KOKU-Nut app, engaged 3 times a week for 12 weeks
Number of subjects: 36
Study 38687981 — intervention group
Group type: COMPARATOR
Intervention: Leaflet promoting a healthy lifestyle (Control)
Number of subjects: 36
Study 38687981 — intervention group
Group type: EXPERIMENTAL
Intervention: KOKU-Nut app
Number of subjects: 36
Study 38688118 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine (0.5 mg/kg, adjusted according to individual responses)
Number of subjects: 26
Study 38688118 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine
Number of subjects: 26
Study 38688164 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (valA)
Number of subjects: 137
Study 38688164 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir (valG)
Number of subjects: 137
Study 38688344 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-106a-5p
Number of subjects: 170
Study 38688344 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-484
Number of subjects: 170
Study 38688344 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-miRNA panel (miR-106a-5p and miR-484)
Number of subjects: 170
Study 38688665 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose metformin (500 mg two times per day)
Number of subjects: 0
Study 38688665 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metformin (1000 mg two times per day)
Number of subjects: 0
Study 38688665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38688666 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative cuff-leak test (qtCLT) performed within an hour of planned extubation.
Number of subjects: 900
Study 38688674 — intervention group
Group type: EXPERIMENTAL
Intervention: TARANG intervention (life skills and reproductive health empowerment group-based intervention)
Number of subjects: 800
Study 38688674 — intervention group
Group type: COMPARATOR
Intervention: Usual services in the community (control group)
Number of subjects: 800
Study 38688675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg once daily as an add-on to ongoing SSRI treatment for 8 weeks
Number of subjects: 0
Study 38688675 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily as an add-on to ongoing SSRI treatment for 8 weeks
Number of subjects: 0
Study 38688675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg once daily
Number of subjects: 0
Study 38688870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium magnetic resonance imaging (23Na-MRI)
Number of subjects: 38
Study 38688958 — intervention group
Group type: EXPERIMENTAL
Intervention: Video clip-integrated doctor-patient discharge discussion
Number of subjects: 144
Study 38688958 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal instructions (control)
Number of subjects: 144
Study 38688998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal parent's own milk (IPOM), given ideally twice daily until 28 days of age.
Number of subjects: 37
Study 38689060 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1)
Number of subjects: 60
Study 38689060 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and relatlimab (anti-LAG-3)
Number of subjects: 60
Study 38689167 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment questionnaires about CRF, sleep disturbances, and emotional symptoms; accelerometer for physical activity and sleep quality; cognitive, neuromuscular, and exercise metabolism evaluations.
Number of subjects: 65
Study 38689218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Number of subjects: 66
Study 38689233 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 108
Study 38689233 — intervention group
Group type: COMPARATOR
Intervention: No BCG vaccination (BCG-naïve)
Number of subjects: 108
Study 38689245 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 30
Study 38689245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 38689256 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated exposure treatment (cET) delivered during four consecutive days
Number of subjects: 163
Study 38689269 — intervention group
Group type: EXPERIMENTAL
Intervention: ddPCR-MRD positive patients (non-DTA genes)
Number of subjects: 152
Study 38689269 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ddPCR with multiparameter flow cytometry (MFC)
Number of subjects: 152
Study 38689269 — intervention group
Group type: EXPERIMENTAL
Intervention: ddPCR-MRD positivity of non-DTA genes
Number of subjects: 152
Study 38689304 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted BEP provision based on baseline nutritional status (Arm 2)
Number of subjects: 0
Study 38689304 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted BEP supplementation based on baseline nutritional status and monthly gestational weight gain monitoring (Arm 3)
Number of subjects: 0
Study 38689304 — intervention group
Group type: COMPARATOR
Intervention: Control (Arm 1)
Number of subjects: 0
Study 38689304 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal BEP provision (Arm 4)
Number of subjects: 0
Study 38689310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent IV paracetamol
Number of subjects: 194
Study 38689310 — intervention group
Group type: COMPARATOR
Intervention: Continuous morphine
Number of subjects: 194
Study 38689313 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnodynamic method for measuring end-expiratory lung volume (EELVCO)
Number of subjects: 46
Study 38689313 — intervention group
Group type: COMPARATOR
Intervention: Absolute and corrected EELVCT
Number of subjects: 46
Study 38689324 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy treatments (up to five massages within a 4-month period)
Number of subjects: 75
Study 38689324 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy treatments
Number of subjects: 75
Study 38689346 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 234
Study 38689346 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 234
Study 38689402 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdissociative ketamine infusion (KI)
Number of subjects: 300
Study 38689402 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 300
Study 38689404 — intervention group
Group type: EXPERIMENTAL
Intervention: Various preoperative, intraoperative, and postoperative risk factors for CSA-AKI
Number of subjects: 0
Study 38689404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 ratio
Number of subjects: 0
Study 38689404 — intervention group
Group type: COMPARATOR
Intervention: Other diagnostic biomarkers
Number of subjects: 0
Study 38689737 — intervention group
Group type: EXPERIMENTAL
Intervention: Phthalates (specifically Monobenzyl phthalate - MBzP)
Number of subjects: 426
Study 38689737 — intervention group
Group type: EXPERIMENTAL
Intervention: Phthalates (MnBP and DiNP)
Number of subjects: 426
Study 38689737 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenols and phthalates (as a mixture)
Number of subjects: 426
Study 38689737 — intervention group
Group type: EXPERIMENTAL
Intervention: Phthalate metabolites
Number of subjects: 426
Study 38689774 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID period (including lockdown periods)
Number of subjects: 374
Study 38689774 — intervention group
Group type: COMPARATOR
Intervention: Before COVID
Number of subjects: 374
Study 38689829 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake prone position (APP)
Number of subjects: 61
Study 38689829 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 61
Study 38690606 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9567 72 mg daily
Number of subjects: 46
Study 38690606 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9567 40 mg daily
Number of subjects: 46
Study 38690606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 38690606 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 40 mg daily
Number of subjects: 46
Study 38690606 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 20 mg daily
Number of subjects: 46
Study 38690606 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 5 mg daily
Number of subjects: 46
Study 38690659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 0
Study 38690659 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 38690733 — intervention group
Group type: EXPERIMENTAL
Intervention: Early upregulation of immunosuppressive metabolites and elevated levels of inflammatory cytokines, signatures of coagulation, formation of neutrophil extracellular traps, and T cell functional dysregulation.
Number of subjects: 1152
Study 38690733 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced total plasma Igs and B cells and dysregulated IFN responsiveness among critically ill patients.
Number of subjects: 1152
Study 38690733 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance disruption between IFN-stimulated genes and IFN inhibitors.
Number of subjects: 1152
Study 38690892 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 999
Study 38690892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 999
Study 38690929 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Pressure Variability (BPV) measured as Standard Deviation (SD) and Average Real Variability (ARV)
Number of subjects: 5700
Study 38690929 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Pressure Variability (BPV) measured as Average Real Variability (ARV) and Standard Deviation (SD)
Number of subjects: 5700
Study 38690929 — intervention group
Group type: COMPARATOR
Intervention: Intensive blood pressure control
Number of subjects: 5700
Study 38691209 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-platelet-rich fibrin (L-PRF) with coronally advanced flap (CAF)
Number of subjects: 12
Study 38691209 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG) with coronally advanced flap (CAF)
Number of subjects: 12
Study 38691272 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 151
Study 38691272 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 151
Study 38691272 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 151
Study 38691316 — intervention group
Group type: EXPERIMENTAL
Intervention: Palopegteriparatide treatment
Number of subjects: 82
Study 38691346 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-07799933
Number of subjects: 0
Study 38691346 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-07799933 ± binimetinib
Number of subjects: 0
Study 38691353 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 + No. 10 group
Number of subjects: 526
Study 38691353 — intervention group
Group type: COMPARATOR
Intervention: D2 group
Number of subjects: 526
Study 38691387 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline-trospium chloride (maximum dose xanomeline 125 mg/trospium 30 mg)
Number of subjects: 256
Study 38691387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 38691387 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline-trospium chloride
Number of subjects: 256
Study 38691408 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourced HIV partner services intervention
Number of subjects: 121
Study 38691408 — intervention group
Group type: COMPARATOR
Intervention: Conventional HIV partner services (control)
Number of subjects: 121
Study 38691409 — intervention group
Group type: EXPERIMENTAL
Intervention: Before COVID-19
Number of subjects: 0
Study 38691409 — intervention group
Group type: COMPARATOR
Intervention: During/after COVID-19
Number of subjects: 0
Study 38691582 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 500
Study 38691582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 38691622 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem progenitor cell-gene therapy (HSPC-GT)
Number of subjects: 8
Study 38691679 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation
Number of subjects: 0
Study 38691823 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-pelvic radiation therapy (WPRT)
Number of subjects: 350
Study 38691823 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) and radiation therapy (RT)
Number of subjects: 350
Study 38692113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) group therapy (n=49)
Number of subjects: 95
Study 38692113 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n=46)
Number of subjects: 95
Study 38692292 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant ADAMTS13 (40 IU per kilogram of body weight, administered intravenously)
Number of subjects: 48
Study 38692292 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (plasma-derived products)
Number of subjects: 48
Study 38692292 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant ADAMTS13
Number of subjects: 48
Study 38692292 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 48
Study 38692399 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion dysregulation (DER)
Number of subjects: 183
Study 38692428 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) tailored for adolescents with T1D; specific dosage and duration not mentioned.
Number of subjects: 0
Study 38692428 — intervention group
Group type: COMPARATOR
Intervention: Control curricula; specific details not provided.
Number of subjects: 0
Study 38692511 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT workshop (delivered in two 1.5-h sessions over two weeks)
Number of subjects: 26
Study 38692712 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacologist-led intervention including a detailed discharge medication management plan, a circle of care handover and early postdischarge virtual check-up visits to 1 month with 3-month follow-up.
Number of subjects: 56
Study 38692712 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacologist-led intervention
Number of subjects: 56
Study 38692712 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 56
Study 38692713 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality assessment method for fear of falling (FOF)
Number of subjects: 0
Study 38692713 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires and neurophysiological assessments
Number of subjects: 0
Study 38692713 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement and gait parameters
Number of subjects: 0
Study 38692713 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression model analysis
Number of subjects: 0
Study 38692713 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic analysis of qualitative data
Number of subjects: 0
Study 38692728 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait-focused physiotherapy (GPT) and matching home-based exercise
Number of subjects: 144
Study 38692728 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (SPT) and matching home-based exercise
Number of subjects: 144
Study 38692727 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab (160 mg)
Number of subjects: 39
Study 38692727 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline 0.9% sodium chloride)
Number of subjects: 39
Study 38692732 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital InFlammation Test (GIFT)
Number of subjects: 0
Study 38692824 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime (months 0, 1, 3) with protein boost (months 6 and 8)
Number of subjects: 60
Study 38692824 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-protein coadministration (months 0, 1, 3, 6, and 8)
Number of subjects: 60
Study 38692824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 38693149 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination and HPV-based screening
Number of subjects: 26125
Study 38693149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic transmission modelling
Number of subjects: 26125
Study 38693149 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline results
Number of subjects: 26125
Study 38693271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral cold water spray
Number of subjects: 110
Study 38693271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cold water spray)
Number of subjects: 110
Study 38693314 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDCS (2 mA for 20 min)
Number of subjects: 10
Study 38693314 — intervention group
Group type: COMPARATOR
Intervention: sham ctDCS
Number of subjects: 10
Study 38693511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol 1800 mg/day
Number of subjects: 80
Study 38693511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 38693515 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise program for 12 weeks
Number of subjects: 30
Study 38693515 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 30
Study 38693528 — intervention group
Group type: EXPERIMENTAL
Intervention: App with individualized motivational text messages
Number of subjects: 200
Study 38693528 — intervention group
Group type: COMPARATOR
Intervention: Control group using the smartphone PHR app
Number of subjects: 200
Study 38693528 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 38693537 — intervention group
Group type: EXPERIMENTAL
Intervention: DSD-1VL (entry into DSD at six months after ART initiation after one suppressed viral load)
Number of subjects: 90
Study 38693537 — intervention group
Group type: EXPERIMENTAL
Intervention: DSD-2VL (entry into DSD at six months after ART initiation after two consecutive suppressed viral loads)
Number of subjects: 90
Study 38693537 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 90
Study 38693537 — intervention group
Group type: EXPERIMENTAL
Intervention: DSD-1VL and DSD-2VL combined
Number of subjects: 90
Study 38693537 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level acceptability (clinical elements)
Number of subjects: 90
Study 38693537 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level acceptability (non-clinical elements)
Number of subjects: 90
Study 38693583 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (25 mg/kg), moxifloxacin (400 mg), pyrazinamide, isoniazid, aspirin (150 mg), and steroids for 2 months followed by rifampicin, isoniazid, and pyrazinamide for 4 months
Number of subjects: 372
Study 38693583 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin, isoniazid, pyrazinamide (without aspirin) for 2 months followed by rifampicin, isoniazid, and pyrazinamide for 4 months
Number of subjects: 372
Study 38693583 — intervention group
Group type: COMPARATOR
Intervention: Treatment according to the National TB Elimination Program guidelines
Number of subjects: 372
Study 38694233 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvaliase treatment
Number of subjects: 261
Study 38694503 — intervention group
Group type: EXPERIMENTAL
Intervention: XAV-19 (150 mg)
Number of subjects: 279
Study 38694503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 38694931 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective observational study of AHF management and outcomes
Number of subjects: 7000
Study 38694984 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home-based multicomponent exercise program (MEP)
Number of subjects: 60
Study 38694999 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine infusions
Number of subjects: 0
Study 38695087 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter defibrillator (S-ICD)
Number of subjects: 503
Study 38695087 — intervention group
Group type: COMPARATOR
Intervention: Transvenous ICD (TV-ICD)
Number of subjects: 503
Study 38695087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both S-ICD and TV-ICD
Number of subjects: 503
Study 38695087 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD
Number of subjects: 503
Study 38695107 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) urine tenofovir testing
Number of subjects: 30
Study 38695107 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-level feedback from urine testing
Number of subjects: 30
Study 38695107 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation of urine tenofovir results
Number of subjects: 30
Study 38695107 — intervention group
Group type: EXPERIMENTAL
Intervention: White coat dosing behavior
Number of subjects: 30
Study 38695123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 260
Study 38695123 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 260
Study 38695191 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Intelligence Training (SIT) program
Number of subjects: 200
Study 38695191 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition focusing on healthy living habits
Number of subjects: 200
Study 38695310 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RBD-based VLP vaccine (LYB001) at doses of 30 or 60 µg
Number of subjects: 100
Study 38695310 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2 RBD-based protein subunit vaccine (ZF2001, control group)
Number of subjects: 100
Study 38695372 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the Leg Activity Measure (Tr-LegA)
Number of subjects: 0
Study 38695372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tr-LegA Passive and Active Function Scales
Number of subjects: 0
Study 38695396 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring program for dementia caregivers
Number of subjects: 38